Citius Oncology (CTOR) Accounts Payables (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Accounts Payables data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 71.34% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 71.34% decrease from a year earlier, with the FY2025 full-year figure at $13.2 million, up 256.57% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.2 million, down from $2.7 million in the prior quarter.
• Over the last five years, Accounts Payables for CTOR reached as high as $13.2 million in Q3 2025 and fell as low as $1.3 million in Q3 2023.
• Historically, Accounts Payables has averaged $5.7 million across 4 years, with a median of $4.8 million in 2024.
• Across the five-year window, Accounts Payables surged 256.57% in 2025 and plunged 71.34% in 2026, its largest moves.
• Year by year, Accounts Payables stood at $1.3 million in 2023, then soared by 355.73% to $5.9 million in 2024, then tumbled by 54.04% to $2.7 million in 2025, then declined by 18.52% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $2.2 million in Q1 2026, $2.7 million in Q4 2025, and $13.2 million in Q3 2025.